No Data
No Data
Northern funds trend|Northern funds net buy 0.239 billion yuan, domestic investors continue to increase their holdings of alibaba (09988), with a total of over 16.4 billion Hong Kong dollars accumulated this week.
On September 13, the Hong Kong stock market saw a net buy of HKD 0.239 billion by northbound funds, with a net sell of HKD 0.622 billion through the Shanghai-Hong Kong Stock Connect and a net buy of HKD 0.861 billion through the Shenzhen-Hong Kong Stock Connect.
Hong Kong stock concept tracking | National Medical Products Administration accelerates the approval of clinical pharmaceuticals, institutions bullish on the high-speed development and profit period of innovative drugs (with concept stocks)
National Medical Products Administration: Accelerate the evaluation and approval of clinically urgent products and include eligible products in the priority evaluation and approval process.
Unusual movement: akeso's stock soared during trading hours, with a sales increase of over 40% as rated by small layup, Evoke's head-to-head K drug achieves significant PFS efficacy.
Akeso biopharma soared during trading hours, up 7.37% to HKD 60.45 at the time of writing, with a turnover of HKD 0.666 billion.
Hong Kong stock concept tracking | Overnight, Summit's soaring continues; the value of Akeso may be discovered by the market (with concept stocks).
As a completely China-born dual-targeting drug, AK112 will undoubtedly make overseas pharmaceutical companies and institutional investors pay more attention to the potential exploration of China's original innovative drugs.
Soochow Securities: Domestic innovative drugs are highly competitive globally, and going global is still a major direction.
Compared to the Chinese market, some developed countries overseas show higher payment capability in the innovative drug market, providing a broader pricing space for innovative drugs, thus bringing higher returns for the research and development of innovative drugs.
Guosen Securities maintains its “outperform the market” rating on Akeso (09926), expecting the new lung cancer drug to become a blockbuster product.
Guosen Securities released research reports, stating that Akeso (09926) has made progress in the clinical data of the lung cancer targeted pharmaceutical Yivitro, demonstrating significant efficacy compared to existing targeted pharmaceuticals in first-line lung cancer indications, with good safety, indicating that Yivitro has fully demonstrated the potential of the next generation immune checkpoint inhibitors. Yivitro has been approved in China for EGFRmNSCLC2L indications and will participate in year-end medical insurance negotiations. The bank pointed out that Akeso continues to validate the potential of FIC&BIC, and the company is collaborating with Summit to advance clinical trials globally. Car
No Data
No Data
MayFlower : It was predictable..
Midnite52 : yep